Stellar Biotechnologies revenues nearly doubled in first quarter
Stellar Biotechnologies revenues nearly doubled but so did the company’s losses during the first quarter, the Port Hueneme biotech company reported May 9. Stellar Biotechnologies makes a protein for immunotherapy treatments using a unique sea snail only found off the coastal shores of a small part of California. The company’s revenues increased from $187,627 during Read More →
Stellar Biotechnologies applies for delisting from TSX Venture Exchange
Port Hueneme-based Stellar Biotechnologies has applied for a voluntary delisting from Canada’s TSX Venture Exchange. Stellar makes a protein for immunotherapy treatments using a unique sea snail only found off the coastal shores of a small part of California. Common shares of Stellar Biotechnologies stock started trading on the Nasdaq stock exchange Nov. 5. The Read More →
Port Hueneme’s Stellar Biotechnologies posts mixed earnings results
Stellar Biotechnologies saw revenues increase 130 percent during the first quarter of 2016 but the company still lost more money in 2016 than it did during the same quarter of 2015. The Port Hueneme-based company reported first quarter 2016 results after markets closed Feb. 8. Stellar makes a protein for immunotherapy treatments using a unique Read More →
VC Credit Union maps expansion
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Port Hueneme’s Stellar Biotechnologies trading on Nasdaq
Port Hueneme-based Stellar Biotechnologies started trading on the Nasdaq stock exchange Nov. 5. Stellar makes a protein for immunotherapy treatments using a unique sea snail only found off the coastal shores of a small part of California. Shares opened at $8.74 on Nov. 5 and were trading on the Nasdaq at $9.40 as of 11:30 Read More →